Ülke: İrlanda
Dil: İngilizce
Kaynak: HPRA (Health Products Regulatory Authority)
OXYTETRACYCLINE HYDROCHLORIDE
Norbrook Laboratories Limited
QD06AA03
OXYTETRACYCLINE HYDROCHLORIDE
3.2 %w/v
Cutaneous Spray Solution
POM
Bovine, Ovine, Porcine
Oxytetracycline
Antibacterial
Authorised
1988-10-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Alamycin Aerosol 3.2% w/v Cutaneous Spray, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Cutaneous Spray, solution A blue opaque solution 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle, sheep and pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Alamycin Aerosol is indicated for topical use in the treatment of foot rot in sheep and topical infections caused by organisms sensitive to oxytetracycline in cattle, sheep and pigs. 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to the active substance. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Each 140g aerosol can contains: ACTIVE SUBSTANCE Oxytetracycline 3.2 % w/v (as oxytetracycline hydrochloride) EXCIPIENT Patent Blue V (E131) 0.3 % w/v HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 15/01/2016_ _CRN 7022643_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTION(S) FOR USE IN ANIMALS For external use only. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS Keep away from eyes. Use only in a well ventilated area. Avoid inhalation and contact with skin. Wash hands after use. Wash any splashes immediately. Do not spray on a naked flame or any incandescent material. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) None known. 4.7 USE DURING PREGNANCY, LACTATION OR LAY No adverse effects or foetal abnormalities have been observed following the administration of oxytetracycline aerosol during pregnancy and lactation. 4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERAC Belgenin tamamını okuyun